Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Hepatitis B Vaccine Recombinant Inactivated Poliovirus Vaccine IPV Brand Name – Pediarix
What is Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Hepatitis B Vaccine Recombinant Inactivated Poliovirus Vaccine IPV
Diphtheria Toxoid Tetanus Toxoid Acellular Pertussis Vaccine DTaP Hepatitis B Vaccine Recombinant Inactivated Poliovirus Vaccine IPV (Pediarix), is a combination of five of the seven vaccines that are currently recommended for all children before the first birthday.
The vaccines combined in Pediarix™, along with the Haemophilus influenzae type b (Hib) Vaccine and the Pneumococcal Conjugate Vaccine (PCV) are recommended to be given at 2, 4, and 6 months of age.
The administration of combination vaccines such as Pediarix™ is believed to reduce cost and improve compliance to the vaccination schedule by reducing the number of injections received per physician visit.
The DTP component of the Pediarix™ vaccine is the same as that found in Infanrix® and contains an acellular pertussis vaccine (DTaP). Acellular pertussis vaccine has a significantly lower incidence of local and systemic adverse reactions and better efficacy when compared to whole cell pertussis vaccine (DTwP).
The hepatitis B vaccine component is the same as that found in Engerix-B®.
The inactivated poliovirus vaccine in this product is a new formulation containing an enhanced potency IPV (eIPV), meaning that it has an increased amount of poliovirus antigen per dose compared to formulations that were available before 1987.
In 2000, the CDC recommended the inactivated poliovirus vaccine (IPV) over oral poliovirus vaccine (OPV) for routine childhood polio vaccination in the US.
This recommendation was prompted in part by the the rare but serious side-effect of OPV-associated paralytic poliomyelitis as well as the eradication of wild-type poliovirus from the Western hemisphere.
In general, OPV-only immunization regimens will remain the preferred regimens to control outbreaks associated with wild-type poliovirus, for imminent travel to polio endemic areas, or for special circumstances related to individual patients.
The Pediarix™ vaccine was FDA-approved on December 13, 2002.
Indications
- diphtheria prophylaxis
- hepatitis B prophylaxis
- pertussis prophylaxis
- poliovirus prophylaxis
- tetanus prophylaxis
Side Effects
- alopecia
- aluminum toxicity
- anaphylactic shock
- anaphylactoid reactions
- angioedema
- anorexia
- apnea
- arthralgia
- asthenia
- bronchospasm
- chills
- cyanosis
- diarrhea
- drowsiness
- dyspnea
- elevated hepatic enzymes
- encephalopathy
- erythema
- erythema multiforme
- fatigue
- fever
- Guillain-Barre syndrome
- headache
- hypoesthesia
- hypotension
- hypotonia
- inconsolable crying
- injection site reaction
- insomnia
- intussusception
- irritability
- lethargy
- lymphadenopathy
- maculopapular rash
- malaise
- muscle paralysis
- myelitis
- neuritis
- pallor
- paresthesias
- peripheral neuropathy
- petechiae
- pruritus
- rash
- restlessness
- seizures
- Stevens-Johnson syndrome
- syncope
- urticaria
- vomiting
- weakness
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- anticoagulant therapy
- breast-feeding
- chemotherapy
- children
- coagulopathy
- coma
- encephalopathy
- fever
- geriatric
- Guillain-Barre syndrome
- hemophilia
- hepatitis
- immunosuppression
- infants
- intraarterial administration
- intravenous administration
- latex hypersensitivity
- neomycin hypersensitivity
- neonates
- neurological disease
- polymyxin hypersensitivity
- pregnancy
- premature neonates
- radiation therapy
- seizure disorder
- seizures
- shock
- subcutaneous administration
- thrombocytopenia
- vitamin K deficiency
- yeast hypersensitivity
Interactions
- Hepatitis B Immune Globulin, HBIG
- Ocrelizumab
- Siponimod
